Two scientists at the Fred Hutchinson Cancer Research Center in Seattle have been awarded $16.7 million for stem cell research projects.
Dr. Irwin Bernstein and Beverly Torok-Storb received the federal funding from the National Heart, Lung and Blood Institute. Their award is part of a $170 million effort divided among 18 scientific teams.
Torok-Storb will work with Dr. Mortimer Poncz of Children’s Hospital of Philadelphia to develop molecular and cell-based therapies for a range of blood diseases, using an $8.2 million grant.
Bernstein will work with Edward Morrisey of the University of Pennsylvania to study how biochemical reactions inside cells affect cell
Kim and Jay Case with their dog, Shiloh, at Citizen's Lake Campground in Monmouth on Wednesday morning. Kim won her battle with cancer because of an adult stem cell transplant
When Kim Case was diagnosed with a rare form of cancer, doctors told her she had little chance of survival.
Months later when she was recovering from the disease, they changed their tune.
“The doctors called me their miracle patient,” Case said.
Case, who lives in Gaston, Ore. with her husband, Jay — who’s originally from Monmouth — was diagnosed in August 2004 with a rare form of cancer called NK T-cell
Washington State University researchers provided computer analyses for a new gene therapy study published in Science Translational Medicine.
The study – conducted by the Fred Hutchinson Cancer Research Center in Seattle and published May 9 – found stem cell gene therapy could protect blood cells from damage by chemotherapy in patients suffering from glioblastoma (malignant brain tumors), thereby extending life expectancy.
The WSU laboratory of co-author Grant D. Trobridge, assistant professor of pharmaceutical sciences, developed bioinformatics software that aided the Fred Hutchinson researchers in evaluating the safety of the procedure. The approach was to remove blood stem cells, add a gene
Study May be Key to Unlocking a Cure
An article published in the Summer 2009 edition of Multiple Sclerosis Quarterly Report, a joint publication of United Spinal Association (www.UnitedSpinal.org) and the North American Research Committee on Multiple Sclerosis (NARCOMS), highlights the positive initial results of patients who have improving neurologic function after receiving a stem cell transplant, despite no longer taking any MS medications.
The results are reported in a National Institutes of Health (NIH)-sponsored study called HALT-MS to confirm whether high-dose immunosuppression followed by autologous stem cell transplantation will prevent MS attacks in patients who are not responding to available